Regulatory Considerations and Data Update for Development and Clinical Use for Phage-Based Antimicrobials

A. Decreased psoas muscle mass with reduced functional performance

B. Increased psoas muscle mass with improved functional performance

C. Decreased psoas muscle mass with preserved functional performance

D. Increased psoas muscle mass with preserved functional performance